IL-12, IL-15, and IL-18 pre-activated NK cells target resistant T cell acute lymphoblastic leukemia and delay leukemia development in vivo

References

• Ljunggren HG, Malmberg KJ. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 2007; 7:329-39; PMID:17438573; http://dx.doi.org/10.1038/nri2073
   PubMed Web of Science ®Google Scholar
• Davis ZB, Felices M, Verneris MR, Miller JS. Natural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer. Cancer J 2015; 21:486-91; PMID:26588681; PMID:26264743; http://dx.doi.org/10.1097/PPO.0000000000000156
   PubMed Web of Science ®Google Scholar
• Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nat Immunol 2016; 17:1025-36; PMID:27540992; http://dx.doi.org/10.1038/ni.3518
   PubMed Web of Science ®Google Scholar
• Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol 2013; 31:227-58; PMID:23516982; http://dx.doi.org/10.1146/annurev-immunol-020711-075005
   PubMed Web of Science ®Google Scholar
• Pahl J, Cerwenka A. Tricking the balance: NK cells in anti-cancer immunity. Immunobiology 2017; 222:11-20; PMID:26264743; http://dx.doi.org/10.1016/j.imbio.2015.07.012
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295:2097-100; PMID:11896281; http://dx.doi.org/10.1126/science.1068440
   PubMed Web of Science ®Google Scholar
• Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105:3051-7; PMID:15632206; http://dx.doi.org/10.1182/blood-2004-07-2974
   PubMed Web of Science ®Google Scholar
• Pende D, Marcenaro S, Falco M, Martini S, Bernardo ME, Montagna D, Romeo E, Cognet C, Martinetti M, Maccario R et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 2009; 113:3119-29; PMID:18945967; http://dx.doi.org/10.1182/blood-2008-06-164103
   PubMed Web of Science ®Google Scholar
• Pende D, Spaggiari GM, Marcenaro S, Martini S, Rivera P, Capobianco A, Falco M, Lanino E, Pierri I, Zambello R et al. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood 2005; 105:2066-73; PMID:15536144; http://dx.doi.org/10.1182/blood-2004-09-3548
   PubMed Web of Science ®Google Scholar
• Romanski A, Bug G, Becker S, Kampfmann M, Seifried E, Hoelzer D, Ottmann OG, Tonn T. Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia. Exp Hematol 2005; 33:344-52; PMID:15730858; http://dx.doi.org/10.1016/j.exphem.2004.11.006
   PubMed Web of Science ®Google Scholar
• Pende D, Cantoni C, Rivera P, Vitale M, Castriconi R, Marcenaro S, Nanni M, Biassoni R, Bottino C, Moretta A et al. Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol 2001; 31:1076-86; PMID:11298332; http://dx.doi.org/10.1002/1521-4141(200104)31:4%3c1076::AID-IMMU1076%3e3.0.CO;2-Y
   PubMed Web of Science ®Google Scholar
• Fauriat C, Just-Landi S, Mallet F, Arnoulet C, Sainty D, Olive D, Costello RT. Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood 2007; 109:323-30; PMID:16940427; http://dx.doi.org/10.1182/blood-2005-08-027979
   PubMed Web of Science ®Google Scholar
• Sanchez-Correa B, Morgado S, Gayoso I, Bergua JM, Casado JG, Arcos MJ, Bengochea ML, Duran E, Solana R, Tarazona R. Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands. Cancer Immunol Immunother 2011; 60:1195-205; PMID:21644031; http://dx.doi.org/10.1007/s00262-011-1050-2
   PubMed Web of Science ®Google Scholar
• Hilpert J, Grosse-Hovest L, Grunebach F, Buechele C, Nuebling T, Raum T, Steinle A, Salih HR. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. J Immunol 2012; 189:1360-71; PMID:22730533; http://dx.doi.org/10.4049/jimmunol.1200796
   PubMed Web of Science ®Google Scholar
• Sørskaar D, Lie SO, Førre O. Natural killer cell activity of peripheral blood and bone marrow mononuclear cells from patients with childhood acute lymphoblastic leukemia. Acta Paediatr Scand 1985; 74:433-7; PMID: 3859177; http://dx.doi.org/10.1111/j.1651-2227.1985.tb10998.x
   PubMed Web of Science ®Google Scholar
• Costello RT, Sivori S, Marcenaro E, Lafage-Pochitaloff M, Mozziconacci MJ, Reviron D, Gastaut JA, Pende D, Olive D, Moretta A. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 2002; 99:3661-7; PMID:11986221; http://dx.doi.org/10.1182/blood.V99.10.3661
   PubMed Web of Science ®Google Scholar
• Tajima F, Kawatani T, Endo A, Kawasaki H. Natural killer cell activity and cytokine production as prognostic factors in adult acute leukemia. Leukemia 1996; 10:478-82; PMID: 8642865
   PubMed Web of Science ®Google Scholar
• Stringaris K, Sekine T, Khoder A, Alsuliman A, Razzaghi B, Sargeant R, Pavlu J, Brisley G, de LH, Sarvaria A et al. Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. Haematologica 2014; 99:836-47; PMID:24488563; http://dx.doi.org/10.3324/haematol.2013.087536
   PubMed Web of Science ®Google Scholar
• Lowdell MW, Craston R, Samuel D, Wood ME, O'Neill E, Saha V, Prentice HG. Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. Br J Haematol 2002; 117:821-7; PMID:12060116; http://dx.doi.org/10.1046/j.1365-2141.2002.03495.x
   PubMed Web of Science ®Google Scholar
• Boissel N, Rea D, Tieng V, Dulphy N, Brun M, Cayuela JM, Rousselot P, Tamouza R, Le Bouteiller P, Mahon FX et al. BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia. J Immunol 2006; 176:5108-16; PMID:16585609; http://dx.doi.org/10.4049/jimmunol.176.8.5108
   PubMed Web of Science ®Google Scholar
• Epling-Burnette PK, Bai F, Painter JS, Rollison DE, Salih HR, Krusch M, Zou J, Ku E, Zhong B, Boulware D et al. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood 2007; 109:4816-24; PMID:17341666; http://dx.doi.org/10.1182/blood-2006-07-035519
   PubMed Web of Science ®Google Scholar
• Lee JC, Lee KM, Kim DW, Heo DS. Elevated TGF-β1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 2004; 172:7335-40; PMID:15187109; http://dx.doi.org/10.4049/jimmunol.172.12.7335
   PubMed Web of Science ®Google Scholar
• Dasgupta S, Bhattacharya-Chatterjee M, O'Malley BW, Jr., Chatterjee SK. Inhibition of NK cell activity through TGF-β 1 by down-regulation of NKG2D in a murine model of head and neck cancer. J Immunol 2005; 175:5541-50; PMID:16210663; http://dx.doi.org/10.4049/jimmunol.175.8.5541
   PubMed Web of Science ®Google Scholar
• Crane CA, Han SJ, Barry JJ, Ahn BJ, Lanier LL, Parsa AT. TGF-β downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro Oncol 2010; 12:7-13; PMID:20150362; http://dx.doi.org/10.1093/neuonc/nop009
   PubMed Web of Science ®Google Scholar
• Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG, Steinle A. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003; 102:1389-96; PMID:12714493; http://dx.doi.org/10.1182/blood-2003-01-0019
   PubMed Web of Science ®Google Scholar
• Sanchez-Correa B, Gayoso I, Bergua JM, Casado JG, Morgado S, Solana R, Tarazona R. Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients. Immunol Cell Biol 2012; 90:109-15; PMID:21383766; http://dx.doi.org/10.1038/icb.2011.15
   PubMed Web of Science ®Google Scholar
• Carlsten M, Norell H, Bryceson YT, Poschke I, Schedvins K, Ljunggren HG, Kiessling R, Malmberg KJ. Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J Immunol 2009; 183:4921-30; PMID:19801517; http://dx.doi.org/10.4049/jimmunol.0901226
   PubMed Web of Science ®Google Scholar
• Carlsten M, Baumann BC, Simonsson M, Jädersten M, Forsblom AM, Hammarstedt C, Bryceson YT, Ljunggren HG, Hellström-Lindberg E, Malmberg KJ. Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome. Leukemia 2010; 24:1607-16; PMID:20613786; http://dx.doi.org/10.1038/leu.2010.149
   PubMed Web of Science ®Google Scholar
• Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res 2011; 17:6287-97; PMID:21844012; http://dx.doi.org/10.1158/1078-0432.CCR-11-1347
   PubMed Web of Science ®Google Scholar
• Ni J, Miller M, Stojanovic A, Garbi N, Cerwenka A. Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J Exp Med 2012; 209:2351-65; PMID:23209317; http://dx.doi.org/10.1084/jem.20120944
   PubMed Web of Science ®Google Scholar
• Hüber CM, Doisne JM, Colucci F. IL-12/15/18-preactivated NK cells suppress GvHD in a mouse model of mismatched hematopoietic cell transplantation. Eur J Immunol 2015; 45:1727-35; PMID:25778912; http://dx.doi.org/10.1002/eji.201445200
   PubMed Web of Science ®Google Scholar
• Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, Leong JW, Abdel-Latif S, Schneider SE, Willey S et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med 2016; 8:357ra123; PMID:27655849; http://dx.doi.org/10.1126/scitranslmed.aaf2341
   PubMed Web of Science ®Google Scholar
• Cooper MA, Elliott JM, Keyel PA, Yang L, Carrero JA, Yokoyama WM. Cytokine-induced memory-like natural killer cells. Proc Natl Acad Sci U S A 2009; 106:1915-9; PMID:19181844; http://dx.doi.org/10.1073/pnas.0813192106
   PubMed Web of Science ®Google Scholar
• Leong JW, Chase JM, Romee R, Schneider SE, Sullivan RP, Cooper MA, Fehniger TA. Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells. Biol Blood Marrow Transplant 2014; 20:463-73; PMID:24434782; http://dx.doi.org/10.1016/j.bbmt.2014.01.006
   PubMed Web of Science ®Google Scholar
• Berrien-Elliott MM, Wagner JA, Fehniger TA. Human Cytokine-Induced Memory-Like Natural Killer Cells. J Innate Immun 2015; 7:563-71; PMID:25924651; http://dx.doi.org/10.1159/000382019
   PubMed Web of Science ®Google Scholar
• Romee R, Schneider SE, Leong JW, Chase JM, Keppel CR, Sullivan RP, Cooper MA, Fehniger TA. Cytokine activation induces human memory-like NK cells. Blood 2012; 120:4751-60; PMID:22983442; http://dx.doi.org/10.1182/blood-2012-04-419283
   PubMed Web of Science ®Google Scholar
• Onciu M. Acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2009; 23:655-74; PMID:19577163; http://dx.doi.org/10.1016/j.hoc.2009.04.009
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program 2006; 1:133-41; PMID:17124052; http://dx.doi.org/10.1182/asheducation-2006.1.133
   Google Scholar
• Dibley M, Dorsch S, Roser B. T cell leukaemia in the rat: the pathophysiology. Pathology 1975, 7:219-35; PMID: 1081666; http://dx.doi.org/10.3109/00313027509094412
   PubMed Web of Science ®Google Scholar
• Ahmad F, Hong HS, Jäckel M, Jablonka A, Lu IN, Bhatnagar N, Eberhard JM, Bollmann BA, Ballmaier M, Zielinska-Skowronek M et al. High frequencies of polyfunctional CD8+ NK cells in chronic HIV-1 infection are associated with slower disease progression. J. Virol 2014; 88:12397-408; PMID:25122796; http://dx.doi.org/10.1128/JVI.01420-14
   PubMed Web of Science ®Google Scholar
• Gibbings D, Befus AD. CD4 and CD8: an inside-out coreceptor model for innate immune cells. J Leukoc Biol 2009; 86:251-9; PMID:19401396; http://dx.doi.org/10.1189/jlb.0109040
   PubMed Web of Science ®Google Scholar
• Kveberg L, Jiménez-Royo P, Naper C, Rolstad B, Butcher GW, Vaage JT, Inngjerdingen M. Two complementary rat NK cell subsets, Ly49s3+ and NKR-P1B+, differ in phenotypic characteristics and responsiveness to cytokines. J Leukoc Biol 2010; 88:87-93; PMID:20395458; http://dx.doi.org/10.1189/jlb.0110039
   PubMed Web of Science ®Google Scholar
• Inngjerdingen M, Kveberg L, Vaage JT. A novel NKR-P1Bbright NK cell subset expresses an activated CD25+CX3CR1+CD62L−CD11b−CD27− phenotype and is prevalent in blood, liver, and gut-associated lymphoid organs of rats. J Immunol 2012; 188:2499-508; PMID:22308308; http://dx.doi.org/10.4049/jimmunol.1003939
   PubMed Web of Science ®Google Scholar
• Björkstrom NK, Riese P, Heuts F, Andersson S, Fauriat C, Ivarsson MA, Björklund AT, Flodström-Tullberg M, Michaëlsson J, Rottenberg ME et al. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood 2010; 116:3853-64; PMID:20696944; http://dx.doi.org/10.1182/blood-2010-04-281675
   PubMed Web of Science ®Google Scholar
• Lopez-Vergès S, Milush JM, Pandey S, York VA, Arakawa-Hoyt J, Pircher H, Norris PJ, Nixon DF, Lanier LL. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood 2010; 116:3865-74; PMID:20733159; http://dx.doi.org/10.1182/blood-2010-04-282301
   PubMed Web of Science ®Google Scholar
• Nestvold J, Stokland A, Naper C, Rolstad B. Phenotype and natural killer cell sensitivity of a radiation-induced acute T-cell leukaemia (Roser leukaemia) in PVG rats. Scand J Immunol 2004; 60:153-8; PMID:15238084; http://dx.doi.org/10.1111/j.0300-9475.2004.01436.x
   PubMed Web of Science ®Google Scholar
• De Veirman K, Van Valckenborgh E, Lahmar Q, Geeraerts X, De Bruyne E, Menu E, Van Riet I, Vanderkerken K, Van Ginderachter JA. Myeloid-derived suppressor cells as therapeutic target in hematological malignancies. Front Oncol 2014; 4:349; PMID:25538893; http://dx.doi.org/10.3389/fonc.2014.00349
   PubMedGoogle Scholar
• Li H, Han Y, Guo Q, Zhang M, Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-β 1. J Immunol 2009; 182:240-9; PMID:19109155; http://dx.doi.org/10.4049/jimmunol.182.1.240
   PubMed Web of Science ®Google Scholar
• Nowbakht P, Ionescu MC, Rohner A, Kalberer CP, Rossy E, Mori L, Cosman D, De Libero G, Wodnar-Filipowicz A. Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias. Blood 2005; 105:3615-22; PMID:15657183; http://dx.doi.org/10.1182/blood-2004-07-2585
   PubMed Web of Science ®Google Scholar
• Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B, Tom I, Ivelja S, Refino CJ, Clark H et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat. Immunol 2009; 10:48-57; PMID:19011627; http://dx.doi.org/10.1038/ni.1674
   PubMed Web of Science ®Google Scholar
• Germain C, Guillaudeux T, Galsgaard ED, Hervouet C, Tekaya N, Gallouet AS, Fassy J, Bihl F, Poupon G, Lazzari A et al. Lectin-like transcript 1 is a marker of germinal center-derived B-cell non-Hodgkin's lymphomas dampening natural killer cell functions. Oncoimmunology 2015; 4:e1026503; PMID:26405582; http://dx.doi.org/10.1080/2162402X.2015.1026503
   PubMed Web of Science ®Google Scholar
• Stegmann KA, De Souza JB, Riley EM. IL-18-induced expression of high-affinity IL-2R on murine NK cells is essential for NK-cell IFN-γ production during murine Plasmodium yoelii infection. Eur J Immunol 2015; 45:3431-40; PMID:26420375; http://dx.doi.org/10.1002/eji.201546018
   PubMed Web of Science ®Google Scholar
• Sun JC, Madera S, Bezman NA, Beilke JN, Kaplan MH, Lanier LL. Proinflammatory cytokine signaling required for the generation of natural killer cell memory. J Exp Med 2012; 209:947-54; PMID:22493516; http://dx.doi.org/10.1084/jem.20111760
   PubMed Web of Science ®Google Scholar
• Zhuo M, Fujiki M, Wang M, Piard-Ruster K, Wai LE, Wei L, Martinez OM, Krams SM. Identification of the rat NKG2D ligands, RAE1L and RRLT, and their role in allograft rejection. Eur J Immunol 2010; 40:1748-57; PMID:20306467; http://dx.doi.org/10.1002/eji.200939779
   PubMed Web of Science ®Google Scholar
• Sudworth AD, Ke-Zheng D, Vaage JT, Kveberg L. Degranulation response in cytotoxic rat lymphocytes measured with a novel CD107a antibody. Front Immunol 2016; 7:572; PMID: 28003815; http://dx.doi.org/10.3389/fimmu.2016.00572
   PubMed Web of Science ®Google Scholar
• Vaage JT, Naper C, Løvik G, Lambracht D, Rehm A, Hedrich HJ, Wonigeit K, Rolstad B. Control of rat natural killer cell-mediated allorecognition by a major histocompatibility complex region encoding nonclassical class I antigens. J Exp Med 1994; 180:641-51; PMID:8046337; http://dx.doi.org/10.1084/jem.180.2.641
   PubMed Web of Science ®Google Scholar